Welcome to our dedicated page for EVELO BIOSCIENCES news (Ticker: EVLO), a resource for investors and traders seeking the latest updates and insights on EVELO BIOSCIENCES stock.
Evelo Biosciences, Inc. (Nasdaq: EVLO) is a clinical-stage biotechnology company committed to transforming the lives of patients worldwide by developing innovative medicines known as monoclonal microbials. These therapies are orally administered and designed to modulate systemic immunology and biology by interacting directly with human cells in the gut.
Evelo’s groundbreaking approach leverages the small intestinal axis (SINTAX) to develop medicines that hold promise for a wide range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, and neuroinflammatory conditions, as well as cancer. The company's monoclonal microbials are poised to revolutionize traditional drug discovery and development by enhancing speed, reducing costs, and increasing the success rate of therapeutic outcomes.
Recent achievements at Evelo include the ongoing development of EDP2939, a next-generation product candidate for moderate psoriasis, which builds on the positive Phase 2 clinical data of its predecessor, EDP1815. Despite challenges in recent trials, Evelo remains dedicated to advancing its SINTAX platform and pursuing strategic alternatives for further development and potential partnerships.
Financially, Evelo has recently secured additional financing and restructured its debt, providing the resources needed to continue its clinical programs into 2024. The company aims to deliver therapies that are not only effective and safe but also affordable, addressing the unmet needs of millions of patients with inflammatory diseases.
Founded within VentureLabs® by Flagship Pioneering, Evelo Biosciences is a testament to innovative biotechnology with a mission to discover and develop transformative medicines for a wide array of conditions.
For more information, please visit www.evelobio.com or contact their investor and media relations teams at ir@evelobio.com and media@evelobio.com.
Evelo Biosciences (Nasdaq: EVLO) announced positive Phase 2 clinical data for EDP1815, aimed at treating psoriasis, with a significant reduction in the Psoriasis Area and Severity Index (PASI) score. The treatment demonstrated efficacy in mild to moderate psoriasis, potentially addressing the unmet needs of 85% of psoriasis patients. Financially, the company reported a net loss of $28.7 million for Q4 2021, with cash reserves at $68.4 million. Upcoming milestones include the finalization of registration trials in psoriasis and continued progress in atopic dermatitis trials.
Evelo Biosciences (Nasdaq:EVLO) announced a conference call for March 24, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results and business highlights. The live call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international) with the conference ID 6076311. Evelo is focused on developing SINTAX™ medicines for inflammatory diseases, with three product candidates—EDP1815, EDP1867, and EDP2939—currently under development. More information is available on their website.
Evelo Biosciences (Nasdaq:EVLO) is hosting a virtual event on March 11, 2022, at 8:00 a.m. ET, discussing advancements in psoriasis treatment and the potential of SINTAX™ medicines. Experts Bruce Strober and Daniel Roling will highlight the unmet needs in psoriasis care. The event will be streamed live on Evelo's website, with an archived version available for 30 days post-event. Evelo is developing innovative, orally delivered therapies aimed at treating inflammatory diseases, currently progressing three lead candidates: EDP1815, EDP1867, and EDP2939.
Evelo Biosciences, a clinical stage biotechnology company, will have its CEO, Simba Gill, participate in a panel discussion titled “GI/Microbiome” at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET. The event will be webcast live through Evelo’s investor relations website, with a replay available for 30 days. Evelo is focused on developing SINTAX™ medicines for inflammatory diseases, with three product candidates—EDP1815, EDP1867, and EDP2939—in development.
Evelo Biosciences (Nasdaq: EVLO) announced promising data from the post-treatment follow-up of its Phase 2 trial for EDP1815, an oral treatment for mild and moderate psoriasis. 60% of patients maintained a PASI-50 or greater response at 24 weeks post-treatment, with 30% achieving PASI-75 or greater. The treatment demonstrated durability and safety, with no rebound effects after discontinuation. Evelo plans to advance EDP1815 towards Phase 3 clinical trials, potentially fulfilling a significant unmet need for effective oral therapies in psoriasis.
Evelo Biosciences (Nasdaq:EVLO) initiated its Phase 2 clinical trial, EDP1815-207, for the treatment of atopic dermatitis, enrolling approximately 300 patients across 60 sites. Dosing has begun for patients with varying severities of the condition. The trial aims to assess the efficacy of EDP1815, which has shown promise in earlier studies for psoriasis. Topline results are expected in the first half of 2023. This investigational oral medicine targets systemic inflammation and is designed to provide a new treatment option for individuals suffering from atopic dermatitis.
Evelo Biosciences (Nasdaq: EVLO) announced significant findings from its Phase 2 trial of EDP1815, an oral treatment for mild to moderate psoriasis. The study demonstrated a statistically significant reduction in pro-inflammatory cytokines IL-6, IL-8, and TNF after 16 weeks of dosing. Skin biopsies of six patients showed reductions in IL-12b, IL-17, and IL-23, supporting EDP1815's potential in treating psoriasis and atopic dermatitis. Evelo plans to advance EDP1815 to Phase 3 trials and expects six-month follow-up data soon.
Evelo Biosciences (Nasdaq:EVLO) announced new data on EDP1815, its lead product for treating inflammatory diseases like psoriasis and atopic dermatitis. Presented at the 2022 Winter Clinical Dermatology Congress, the data elucidates EDP1815's mechanism, showing its ability to modulate systemic inflammation via innate immune receptors. This supports further development, with ongoing Phase 2 trials for psoriasis and soon-to-start trials for atopic dermatitis. EDP1815 is a non-live oral medicine targeting gut inflammation without altering the microbiome.
Evelo Biosciences (Nasdaq:EVLO) announced its strategic priorities for 2022, focusing on developing SINTAX™ medicines for inflammatory diseases. The company reported positive Phase 2 data for EDP1815 in psoriasis, highlighting its oral delivery method and safety profile. In 2022, Evelo aims to advance EDP1815 towards Phase 3 trials, initiate a global Phase 2 trial in atopic dermatitis, and develop additional candidates like EDP1867 and EDP2939. Key catalysts expected include clinical data releases and trial initiations over the next 12-18 months.
Evelo Biosciences, a clinical stage biotech company, announced its addition to the NASDAQ Biotechnology Index, effective December 20, 2021. This index tracks biotechnology and pharmaceutical securities listed on Nasdaq, with companies required to meet specific eligibility criteria. Evelo is developing SINTAX™ medicines for inflammatory diseases and cancer, with four product candidates: EDP1815, EDP1867, EDP2939, and EDP1908. The inclusion in the index may enhance visibility and credibility, positively impacting investor interest.
FAQ
What is the current stock price of EVELO BIOSCIENCES (EVLO)?
What is the market cap of EVELO BIOSCIENCES (EVLO)?
What does Evelo Biosciences specialize in?
What diseases are Evelo's medicines targeting?
What is the SINTAX platform?
What is EDP2939?
Who founded Evelo Biosciences?
Has Evelo secured financing recently?
What recent trials has Evelo conducted?
What is the mission of Evelo Biosciences?
How can I contact Evelo Biosciences for investor information?
Where can I find more information about Evelo Biosciences?
